-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：麦格纳国际（MGA）公布第一季度调整后每股收益为1.38美元，高于预期的0.78美元（增长77%），远超市场普遍预期的1.01美元。这主要得益于远超预期的销售额和利润率。营收增长3.1%至103.8亿美元（比市场普遍预期高出1.1亿美元），调整后息税前利润率提升190个基点至5.4%（比市场普遍预期高出120个基点）。MGA将2026年营收预期从419亿至435亿美元下调至415亿至431亿美元（目前市场普遍预期为424亿美元）。除上述调整外，MGA将净利息支出预期从1.8亿美元下调至1.65亿美元。其他业绩预期保持不变。尽管该公司并未上调全年每股收益预期，但鉴于业绩远超预期，我们认为上调预期的可能性更大。不过，考虑到当前宏观经济的不确定性，管理层的谨慎态度也情有可原。鉴于MGA在汽车零部件和设备领域拥有广泛的产品多元化，并且是北美最大的汽车供应商，我们认为其第一季度强劲的业绩对其他汽车供应商具有积极意义。
Related Articles
Research
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
$INCY
Australia
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
$GSK
International
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.